DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer.
Anna I BrichkinaMiriam EmsRoman SuezovRajeev SinghVeronika LutzFelix S R PicardAndrea NistThorsten StieweJohannes GraumannMichael DaudeWibke E DiederichFlorian FinkernagelHo-Ryun ChungDetlef K BartschKatrin RothCorinna KeberCarsten DenkertMagdalena HuberThomas M GressMatthias LauthPublished in: Gut (2024)
In light of DYRK inhibitors currently entering clinical phase testing, our data thus provide a novel and clinically translatable approach targeting both the cancer cell compartment and its microenvironment.